News >

Novel Combo Shows Early Promise in Ovarian Cancer

Jason Harris
Published: Friday, May 05, 2017

Sanaz Memarzadeh, MD, PhD

Sanaz Memarzadeh, MD, PhD

Preclinical findings showed that the combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma (HGSC) ovarian tumor cells.

Flow cytometry detected no surviving cells and cells did not grow when passaged after treatment in 13 samples, indicating sensitivity to the combination. sensitive. Researchers determined that the remaining samples were resistant because of >1% cell survival and robust growth upon passaging. Monotherapy did not have any effect on HGSCs.
La V, Fujikawa R, Janzen DM, et al. Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy [published online April 3, 2017]. npj Precision Oncology. doi: 10.1038/s41698-017-0008-z.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication